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Microarray-based transcriptional profiling was used to determine the effect of nicotinamide
on gene expression in an experimental traumatic brain injury (TBI) model. Ingenuity Path-
way Analysis (IPA) was used to evaluate the effect on relevant functional categories and
canonical pathways. At 24 h, 72 h, and 7 days, respectively, 70, 58, and 76%, of the differ-
entially expressed genes were up-regulated in the vehicle treated compared to the sham
animals. At 24 h post-TBI, there were 150 differentially expressed genes in the nicotinamide
treated animals compared to vehicle; the majority (82%) down-regulated. IPA analysis
identified a significant effect of nicotinamide on the functional categories of cellular move-
ment, cell-to-cell-signaling, antigen presentation and cellular compromise, function, and
maintenance and cell death. The canonical pathways identified were signaling pathways
primarily involved with the inflammatory process. At 72 h post-cortical contusion injury,
there were 119 differentially expressed genes in the nicotinamide treated animals com-
pared to vehicle; the majority (90%) was up-regulated. IPA analysis identified a significant
effect of nicotinamide on cell signaling pathways involving neurotransmitters, neuropep-
tides, growth factors, and ion channels with little to no effect on inflammatory pathways.
At 7 days post-TBI, there were only five differentially expressed genes with nicotinamide
treatment compared to vehicle. Overall, the effect of nicotinamide on counteracting the
effect of TBI resulted in significantly decreased number of genes differentially expressed
by TBI. In conclusion, the mechanism of the effect of nicotinamide on secondary injury
pathways involves effects on inflammatory response, signaling pathways, and cell death.
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INTRODUCTION
The Centers for Disease Control and Prevention have stated that
traumatic brain injury (TBI) is among the leading causes of acute
and chronic disability in the United States and each year 1.7 mil-
lion Americans endure a TBI, and 52,000 die (Faul et al., 2010).
Although more individuals survive TBI than in the past, the
survivors endure residual physical, cognitive, emotional, and/or
behavioral impairments from the cascade of central pathological
responses resulting from TBI.
The field of TBI recognizes two distinct forms or stages of brain
injury. The first or primary injury relates to the initial injury caused
by direct damage to the brain. It is believed that only injury pre-
vention or reduction will reduce the consequences of the primary
injury. The second is indirect and progressive and is referred to as
secondary injury.
The etiology of secondary brain injury is multi-factorial, with
a host of likely inter-related processes including mitochondrial
energy failure, excessive generation of reactive oxygen species,
activation of destructive enzymes such as poly (ADP-ribose) poly-
merase (PARP) and caspase family of proteases,membrane disrup-
tion, neuronal death, thrombosis due to intravascular coagulation
in small vessels, increased synaptic concentrations of excitatory
amino acids, and activation of innate inflammatory responses
(Schouten, 2007). To date, no single pharmacological agent has
been shown to improve the outcome of TBI. Several reviews have
suggested the need for pharmacological treatments that target
multiple secondary factors or combination treatment strategies
(Faden and Stoica, 2007; Schouten, 2007).
Nicotinamide has been shown to improve neurological out-
come and reduce the amount of tissue damage in various animal
models TBI (Hoane et al., 2003, 2006a,b,c, 2008a,b; Holland et al.,
2008; Goffus et al., 2010; Vonder Haar et al., 2011) and stroke
(Ayoub et al., 1999; Sakakibara et al., 2002; Yang et al., 2002a,b,c).
Recovery of function of both sensory and motor tasks after TBI
have been found with a variety of nicotinamide dosing regiments
which include doses ranging from 50 mg/kg to 500 mg/day kg
administered up to 24 h post-injury to sustained infusion studies
using 150 mg/day for 7 days.
Nicotinamide is the precursor of β-nicotinamide adenine
dinucleotide (NAD+) and is important for the synthesis of
nicotinamide adenine dinucleotide phosphate (NADP+). NAD+
and NADP+ are coenzymes that are vital to many oxidation-
reduction reactions in cell metabolism. NAD+ is a precursor for
ATP, and NAD+ increases neuronal ATP concentration (Klaid-
man et al., 1996). After TBI, nicotinamide may prevent the
depletion of NAD+, thus protecting against ATP depletion and
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increasing neuroprotection (Li et al., 2006). Previous experi-
mental studies have demonstrated that nicotinamide has anti-
inflammatory and anti-oxidant effects, prevents apoptosis, and
decreases cerebral edema (for reviews, see Yang and Adams, 2004;
Li et al., 2006). However, the predominance of the preclini-
cal studies evaluating the proposed mechanism of actions of
nicotinamide have evaluated single or multiple 500 mg/kg doses,
which result in peak concentrations of∼300µg/mL (Hoane et al.,
2006c), 10–30 times higher than clinically relevant concentra-
tions. Nicotinamide doses of 1–3 g/day (15–45 mg/kg/day; Knip
et al., 2000) have been administered in the experimental treat-
ment or prevention of diabetes type 2 and result in peak nicoti-
namide serum concentrations of ∼25–70µg/mL (Horsman et al.,
1993).
The objective of this study was to use microarray analysis to
determine the effect of clinically relevant doses of nicotinamide
on gene expression patterns and profiles following experimental
TBI in the rat. By understanding the mechanism of the effect
of nicotinamide on the secondary injury response in TBI, we
can develop future treatment strategies using a combination of
drugs to target the multiple pathways involved in secondary
injury.
MATERIALS AND METHODS
ANIMALS
Male, Sprague-Dawley rats (Harlan, Indianapolis, IN, USA), 4-
months of age were used in this study. All animal and surgical
procedures were adhered to as described in the NIH Guide for
the Care and Use of Laboratory Animals. The Southern Illi-
nois University Institutional Animal Care and Use Committee
(IACUC) and the University of Washington’s IACUC reviewed
and approved all experimental procedures. Before and after injury,
animals were housed in the university-maintained vivarium, with
a 12-h light/dark schedule and a controlled environmental tem-
perature of 22˚C in standard housing cages with food and water
available ad libitum.
PHARMACOKINETIC STUDIES
Male Sprague-Dawley rats (309± 17 g) with surgically implanted
jugular vein catheters were obtained from Harlan Laboratories.
Four animals were anesthetized using a mixture of isoflurane (2–
4%) and oxygen (0.8 L/min). Alzet osmotic mini-pumps (Alzet
model 2ML1, pumping rate of 10µL/h) were implanted subcuta-
neously (s.c.)∼2.0 cm posterior to the scapulae and shifted to the
right of midline. The infusion pumps were weighed prior to and
after loading the nicotinamide solution. After filling, the pumps
were soaked overnight in a water bath at 37˚C, and taken out
just prior to placing in rat to insure that the pump was operat-
ing at the desired flow rate at the time of implantation. Based on
the pharmacokinetic results of a previous single dose study (data
not shown), a loading dose of 75 mg/kg of nicotinamide (Sigma-
Aldrich Co., St. Louis, MO, USA) dissolved in phosphate buffered
saline (PBS) was administered by s.c. injection and an infusion
rate of 12.0 mg/h kg were used to target a steady state concentra-
tion of ∼50µg/mL. Blood samples were collected in microtubes
immediately prior to loading dose, and at 1, 4, 24, 48, and 72 h, and
stored at −80˚C until assayed using a previously published assay
(Goffus et al., 2010).
EXPERIMENTAL INJURY MODEL
The cortical contusion injury (CCI) model utilized in the present
study was based on previous studies and was intended to pro-
duce a moderately severe injury (Quigley et al., 2009; Goffus
et al., 2010; Anderson et al., 2011). Animals, ∼3 months of age
with a weight of 335± 28 g were anesthetized using a mixture
of isoflurane (2–4%) and oxygen (0.8 L/min). When the animal
became unresponsive (no ocular or pedal reflexes) the head was
shaved and scrubbed with 70% alcohol followed by betadine and
placed into a stereotaxic device. A midline incision was made
in the skin as well as through the underlying fascia. A circu-
lar craniotomy (5.0 mm) was centered 2.4 mm posterior to and
2.4 mm lateral (left) to bregma. The contusion injury was cre-
ated with the Benchmark™ stereotaxic impactor with a 4.0-mm
FIGURE 1 | Histology plate. Shown are representative dorsal images of the injury in each group prior to the harvesting of the tissue for analysis. Image bar is
2.0 mm.
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Table 1 | Brain gene expression data.
24 h 72 h 7 days
Down Up Total Down Up Total Down Up Total
Vehicle/sham 351 808 1159 1264 1739 3002 351 1108 1459
NAM/sham 106 621 727 479 1322 1801 247 886 1133
NAM/vehicle 124 26 150 12 107 119 4 1 5
The number of differentially expressed genes (>1.5-fold up or down, p<0.05).
FIGURE 2 |The Venn diagrams show the number of genes whose expression was up or down-regulated more than 1.5-fold (p<0.05) in the
NAM/Sham and Vehicle/Sham contrasts at the 24 h, 72 h, and 7-day time points. Venn diagrams were generated with the Bioconductor limma package
diameter impactor tip (St. Louis, MO, USA)1. A moderate injury
was induced with an impact speed of 3.0 m/s and an impact depth
of 2.5 mm (Swan et al., 2011). The impact tip maintained con-
tact with the brain tissue for 0.5 s before retraction. Normal body
temperature (37˚C) during surgery and recovery was maintained
with a warm water recycling bed and pump system (EZ Anesthe-
sia, Palmer, PA, USA). Four hours post-CCI, osmotic mini-pumps
were implanted as described above. Rats receiving sham surgeries
1www.myneurolab.com
underwent identical surgical preparation as the injured animals
but did not receive craniotomies or injuries, and were then sutured
and allowed to recover.
Based on the pharmacokinetic studies, each animal received a
75-mg/kg s.c. loading dose of nicotinamide or vehicle (1.0 mL/kg
PBS) at time of implantation of the infusion pump 4 h after the
CCI injury. The nicotinamide infusion rate was 12 mg/h kg or vehi-
cle (0.9% PBS) for 72 h post-injury as described above. Animals
were randomly assigned to one of three groups: Group 1: Intact
sham (n= 5), Group 2. CCI injured nicotinamide (n= 15), and
Group 3. CCI injured vehicle (n= 15).
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FIGURE 3 |The top 10 functional categories and canonical pathways
involving significantly regulated genes in the nicotinamide treated
compared to vehicle treated CCI injured animals for the 24-h time
point. The length of the bar is the negative log of the p-value and is
significant if it extends to the right of the threshold line −log(p<0.05). The
ratio number, is defined as the number of significant molecules in the given
pathways divided by the total number of molecules that are included in the
pathway.
TISSUE HARVEST
Five intact sham animals and five animals in each treatment group
at specified time point’s post-CCI (24 h, 72 h, and 7 days) were
overdosed with a mixture of CO2 (80%) and O2 (20%). The rats
were then decapitated; a cardiac blood sample collected and brains
were rapidly extracted. For the animals in the 7-day group, the
infusion pump was explanted under anesthesia at 72 h post-TBI
and a tail snip blood sample was obtained. To maintain quality
control and to assure that all of the brains were injured, each
brain was assigned a rating score (1= no visual sign of trauma;
2= bruised and swollen cortex; 3= no remaining cortex; or exten-
sive damage). Only brains with a score of 2 were used in the
subsequent analyses. An example of representative dorsal images
of the injury in each group prior to the harvesting of the tissue for
analysis is shown in Figure 1.
The brain was then cut into a 4.0-mm coronal slab containing
the injury site in a brain matrix (Braintree Scientific, Inc., Brain-
tree, MA, USA) and was placed onto an RNAase free cold plate
and a 5.0-mm biopsy bunch was used to collect the injury site and
surrounding cortical tissue (Hoane et al., 2006a; Anderson et al.,
2011). The tissue punch included all injured cortical tissue and
a small strip of pericontusional tissue, with the ventral extent of
the punch extending to the corpus callosum. Tissue punches were
placed into microcentrifuge tubes, snap frozen, and then stored
at −80˚C. All samples were shipped by overnight carrier to the
University of Washington on dry ice.
PROCESSING OF SAMPLES FOR MICROARRAY ANALYSIS
Integrity of RNA samples was assessed with an Agilent 2100 Bioan-
alyzer (Agilent Technologies, Inc., Santa Clara, CA, USA) which is
the method of choice and the recognized standard in the field. RNA
integrity was judged by observing distinct and sharp 18 and 28 s
ribosomal RNA peaks that were baseline separated. RNA quantity
was determined by measuring OD260 with a Thermo Scientific
NanoDrop™1000 Spectrophotometer (Thermo Fisher Scientific,
Inc., Wilmington, DE, USA). The NanoDrop instrument was also
used to determine purity of RNA samples by measuring OD260/280
and OD260/230 ratios. Only samples passing this stringent quality
control were processed further. Processing of the RNA samples
was carried out according to the Affymetrix GeneChip Whole
Transcript Sense Target labeling protocol. Briefly, double-stranded
cDNA was synthesized with random hexamers tagged with a T7
promoter sequence. The double-stranded cDNA was subsequently
used as a template and amplified by T7 RNA polymerase produc-
ing many copies of antisense cRNA. In the second cycle of cDNA
synthesis, random hexamers were used to prune reverse transcrip-
tion of the cRNA from the first cycle to produce single-stranded
DNA in the sense orientation. In order to reproducibly fragment
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FIGURE 4 |The top 10 functional categories and canonical pathways
involving significantly regulated genes in the nicotinamide treated
compared to vehicle treated CCI injured animals for the 72-h time
point. The length of the bar is the negative log of the p-value and is
significant if it extends to the right of the threshold line [−log(p<0.05)]. The
ratio number, is defined as the number of significant molecules in the given
pathways divided by the total number of molecules that are included in the
pathway.
the single-stranded DNA and improve the robustness of the assay,
dUTP was incorporated in the DNA during the second cycle, first-
strand reverse transcription reaction. This single-stranded DNA
sample was then treated with a combination of uracil DNA gly-
cosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE
1) that specifically recognizes the unnatural dUTP residues and
breaks the DNA strand. DNA was labeled by terminal deoxynu-
cleotidyltransferase (TdT) with the Affymetrix® proprietary DNA
Labeling Reagent that is covalently linked to biotin. The biotin
labeled DNA fragments were hybridized to Affymetrix GeneChip
Rat Gene 1.0 ST arrays, washed, and stained with fluorescent anti
streptavidin biotinylated antibody. Following an additional wash
step, the arrays were scanned with an Affymetrix GeneChip® 3000
scanner. Image generation and feature extraction was performed
using Affymetrix GeneChip Command Console Software.
ANALYSIS OF THE MICROARRAY DATA
Raw microarray data was processed and analyzed with the Bio-
conductor aroma package (Bengtsson et al., 2008) and normalized
using the RMA method from the Bioconductor Affy package. The
quantile normalization step of the RMA normalization was per-
formed at the probeset level. Using the normalized data, genes with
significant evidence for differential expression were identified with
the limma package (Smyth, 2004) in Bioconductor. The limma
methodology calculates a p-value for each gene using a modified
t -test in conjunction with an empirical Bayesian method to mod-
erate the standard errors of the estimated log-fold changes. This
method of detecting differentially expressed genes draws strength
across genes for more robust and accurate detection of differen-
tially expressed genes. Such an adjustment has repeatedly been
shown to avoid an excess of false positives when identifying differ-
entially expressed genes (Allison et al., 2006). Using the p-values
from limma, we used the Bioconductor package p.adjust (Ben-
jamini and Hochberg, 1995) to estimate the false discovery rate
associated with our list of differentially expressed genes. This
methodology allows us to address the multiple testing problem
without resorting to an excessively conservative approach that con-
trols the familywise error, such as a Bonferroni correction. Venn
diagrams were generated with the Bioconductor limma package.
Ingenuity Pathway Analysis (IPA; Build 131235; Version
11904312; Database Status 02.20.2012)2 was used to analyze
differentially expressed genes (>1.5-fold up or down-regulated,
2www.ingenuity.com
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FIGURE 5 | Cell-to-cell signaling network generated by ingenuity
pathway analysis of differentially expressed genes: Molecules are
represented as nodes, and the biological relationship between two
nodes is represented as an edge (line). All edges are supported by at
least one reference from the literature, from a textbook, or from canonical
information stored in the Ingenuity Knowledge Base. The intensity of the
node color indicates the degree of up- (red) or down- (green) regulation.
Nodes are displayed using various shapes that represent the functional
class of the gene product. Edges are displayed with various labels that
describe the nature of the relationship between the nodes. Top: the
nicotinamide treated injured animals compared to vehicle treated injured
animal. Bottom: the vehicle treated injured animals compared to sham
controls highlighting only the genes affected by nicotinamide treatment
shown in the top figure.
p< 0.05) using the Core Analysis feature. IPA is a commercial
tool that is based on a proprietary database (see text footnote 2)
to facilitate the identification of biological themes, in microarray
gene expression data. IPA uses a Right-tailed Fisher’s exact test to
calculate a p-value determining the probability that each biological
function, canonical pathway, or transcriptional network assigned
to the data set is due to chance alone.
VALIDATION OF DATA OBTAINED WITH MICROARRAYS USING
FLUOROGENIC 5′-NUCLEASE-BASED ASSAY AND QUANTITATIVE
RT-PCR
Quantitative TaqMan based RT-PCR (qPCR) analysis has a greater
dynamic range for changes in gene expression levels compared to
microarray-based analysis. Therefore, we used quantitative-PCR
(qPCR) to validate expression changes of 15 genes of interest
that had been identified by microarray analysis with significant
changes by either TBI or nicotinamide treatment. Briefly, reverse
transcription was performed according to the manufacturer’s
established protocol using total RNA and the SuperScript®III First-
Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). For
gene expression measurements, 2µL of cDNA were included in
a PCR reaction (12µL final volume) that also consisted of the ABI
inventoried TaqMan® Gene Expression Assays mix and the Taq-
Man Gene Expression Master Mix according to the manufacturer’s
protocol (Applied Biosystems, Inc., Foster City, CA, USA). Ampli-
fication and detection of PCR amplicons were performed with the
ABI PRISM 7900 system (Applied Biosystems, Inc., Foster City,
CA, USA) with the following PCR reaction profile: 1 cycle of 95˚C
for 10 min, 40 cycles of 95˚C for 30 s, and 60˚C for 1 min. β-Actin
amplification plots derived from serial dilutions of an established
reference sample were used to create a linear regression formula in
order to calculate expression levels. β-Actin gene expression levels
were utilized as an internal control to normalize the data.
RESULTS
NICOTINAMIDE CONCENTRATIONS
In the healthy animals, 75 mg/kg s.c. bolus plus an infusion rate
of 12.0 mg/h kg of nicotinamide resulted in peak concentrations
of 68± 8µg/mL at 1 h with steady state concentrations of 41± 7,
36± 8, and 33± 9µg/mL at 24, 48, and 72 h post-infusion, respec-
tively. In the CCI injured animals, nicotinamide concentrations
were 45± 12 and 55± 4µg/mL at 24 and 72 h, respectively at time
of sacrifice. The nicotinamide concentrations was 50± 13µg/mL
obtained by tail snip at 72 h at the time of removal of the osmotic
pump in the animals sacrificed at 7 days. Nicotinamide concen-
trations were below the detectable limit at the time of sacrifice at
7 days post-CCI.
GENE EXPRESSION STUDY
The microarray data passed all the standard and advanced qual-
ity control metrics. The number of differentially expressed genes
(>1.5-fold change, p< 0.05) at 24 h, 72 h, and 7 days is presented
in Table 1. The vehicle to sham (no injury) comparison reflects
the effect of the TBI without treatment relative to sham con-
trols. At 24 h, 72 h, and 7 days, respectively, 70, 58, and 76%, of
the differentially expressed genes were up-regulated in the vehi-
cle treated animals compared to the sham animals (Table 1). The
nicotinamide to sham comparison reflects the effect of TBI with
treatment compared to sham controls. The Venn diagrams show
the number of genes differentially expressed more than 1.5-fold
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Table 2 | Regulated genes in the functional categories and canonical pathways at 24 h post-TBI.
Functional categories
Cellular movement Fcar, Trem1, Sell, Anpep, Adam8, Ptprc, Hmox1, Cxcl3, Nfkbia, Cxcr2, Tnfrsf1b, Nos2, Hcar2, Ccl6, Ccr1, Csf3r, Sdc1,
Fcgr2a, Cd36, Alox5ap, F13a1, Itgb2, Clec4e, S1009, Ccl7, Il1rn, Fcer1g, Il1b, Ccl3l1/Ccl3l3, Cyr61, Itgax, Arg1
Cell-to-cell signaling and
interaction
Fcar, Sell, Trem1, Anpep, Fcgr1a, Ptprc, Cxcl3, Hmox1, Nfkbia, Gal, Cxcr2, Tnfrsf1b, Nos2, Ccl6, Hcar2, Csf3r, Ccr1, Sdc1,
Fcgr2A, Cd36, F13a1, Clec5a, Itgb2, Ccl7, Clec4e, S100A9, Il1rn, Fcer1G, Ccl3l1/Ccl3l3, Il1b, Bcl2a1, Cyr61, Slc11a1, Itgax
Antigen presentation Fcar, Trem1, Sell, Fcgr1a, Anpep, Cxcl3, Hmox1, Cxcr2, Tnfrsf1b, Nos2, Hcar2, Csf3r, Ccr1, Sdc1, Fcgr2a, Cd36, Clec5a,
Itgb2, Clec4e, S100a9, Ccl7, Il1rn, Fcer1g, Il1b, Ccl3l1/Ccl3l3, Slc11a1, Itgax, Arg1
Cellular compromise Ccr1, Fcar, Gsta2, Sell, Trem1, Sdc1, Fcgr2a, Anpep, Ptprc, Itgb2, Cxcl3, Hmox1, Sl00a9, Il1rn, Pilra, Fcer1g,
Ccl13l/Ccl3l3, Il1b, Tnfrsf1b, Nos2, Slc11a1, Arg1
Cellular function and
maintenance
Csf3r, Fcar, Ccr1, Sell, Trem1, Fcgr2a, Cd36, Anpep, Fcgr1A, Ptprc, Itgb2, Cxcl3, Ccl7, Fcer1g, Ccl3l1/Ccl3l3, Il1b, Slc11a1
Organismal injury and
abnormalities
Sell, Trem1, Anpep, Fcgr1a, Il1r2, Hmox1, Nfkbia, Hbb, Gal, Cxcr2, Nos2, Tnfrsf1b, Ccl6, Csf3r, Slpi, Fcgr2a, Cd36, F13a1,
Itgb2, Sl00a9, Il1rn, Fcer1g, Il1b, Ccl13l/Ccl3l3, Arg1
Cell signaling Sell, Trem1, Igsf6, Fcgr1a, Ptprc, Il1r2, Cxcl3, Hmox1, Gal, Cxcr2, Tnfrsf1b, Nos2, Ccr1, Fcgr2a, Cd36, Hhip, Itgb2, Ccl7,
S100a9, Il1rn, Fcer1g, Pilr2, Il1b, Ccl3l1/Ccl3l3, Arg1
Molecular transport Trem1, Sell, Fcgr1a, Ptprc, Il1r2, Cxcl3, Hmox1, Nfkbia, Slc6a20, Gal, Cxcr2, Plin2, Nos2, Tnfrsf1b, Hcar2, Ccr1, Fcgr2a,
Cd36, Alox5ap, Sgms2, Itgb2, Ccl7, S100a9, Il1rn, Pilra, Fcer1g, il1b, Ccl3l1/Ccl3l3, Slc11a1, Arg1
Vitamin and mineral
metabolism
Ccr1, Trem1, Sell, Fcgr2a, Fcgr1a, Ptprc, Itgtb2, Cxcl3, Ccl7, S100a9, Gal, Crcx2, Pilra, Fcer1g, Ccl3l1/Ccl3l3, Il1b, Nos2
Cell death Fcar, Trem1, Glipr1, Anpep, Fcgr1a, Adam8, Ptprc, Hmox1, Cxcl3, Hbb, Nfkbia, Gal, Cxcr2, Nos2, Tnfrsf1b, Ccl6, Arl11,
Hcar2, Csf3r, Cd53, Ccr1, Gsta2, Sdc1, Fcgr2a, Cd36, F13a1, Sgms2, Clec5a, Itgb2, S100a9, Ccl7, Il1rn, Fcer1g,
Ccl3l1/Ccl3l3, Brca2, Il1b, Bcl2a1, Cyr61, Arg1
Canonical pathway
Il-10 signaling Il1r2, Ccr1, Hmox1, Nfkbia, Fcgr2a, Il1rn, Il1b
LXR/RXR activation Il1r2, Ccl7, Il1rn, Cd36, Il1b, Tnfrsf1b, Nos2
TREM1 signaling Trem1, Ccl7, Tlr13, Il1b, Itgax
Communication
between innate and
adaptive immune cells
Il1rn, Fcer1g, Ccl13l/Ccl3l3, Tir13, Il1b
PPAR signaling Il1r2, Nfkbia, Il1rn, Il1b, Tnfrsf1b
Il-6 signaling Il1r2, Nfkbia, Il1rn, Il1b, Tnfrsf1b
NF-κB signaling Il1r2, Nfkbia, Il1rn, Fcer1g, Il1b, Tnfrsf1b
Glucocorticoid receptor
signaling
Il1r2, Cxcl3, Nfkbia, Il1rn, Il1b, Nos2, Fcgr1a
Xenobiotic metabolism
signaling
Hmox1, Gsta2, Il1b, Sult1d1, Nos2, Sult2a1
FXR/RXR activation Sdc1, Il1rn, Il1b, Sult2a1
(p< 0.05) in the nicotinamide compared to sham and vehicle
compared to sham contrasts at the 24-h, 72 h, and 7 day time
points (Figure 2). At 24 h, vehicle treatment resulted in increased
expression of 808 genes (>1.5-fold, p< 0.05) compared to non-
injured sham animals, whereas only 621 genes in the nicotinamide
treated animals showed elevated expression. Similarly, at 24 h post-
TBI, mRNA levels of 351 genes were decreased more than 1.5-fold
(p< 0.05) compared to non-injured sham animals, whereas only
106 genes exhibited decreased expression in the nicotinamide
treated animals. At 72 h, vehicle treatment resulted in increased
expression of 1739 genes (>1.5-fold, p< 0.05) compared to non-
injured sham animals, whereas only 1332 genes in the nicoti-
namide treated animals showed elevated expression. In the same
way, 72 h post-TBI, mRNA levels of 1264 genes were decreased
more than 1.5-fold (p< 0.05) compared to non-injured sham ani-
mals, whereas only 479 genes exhibited decreased expression in
the nicotinamide treated animals. By 7 day post-TBI, vehicle treat-
ment resulted in increased expression of 1108 genes (>1.5-fold,
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Table 3 | Regulated genes in the functional categories and canonical pathways at 72 h post-TBI.
Functional pathways
Cell-to-cell signaling and interaction Cacna1g, Kcnh1, Scn2a, Sv2b, Egr3, Cacnb4, Rgs4, Cck, Stx1a, Hrh3, Efna5, Sst, Htr1f, Ptgs2, Chrna5,
Adra1b, Gabra3, Mmp9, Agt, Htr2a
Molecular transport Cacna1g, Kcnh1, Clic5, Scn2a, Slc4a11, Cacnb4, Rgs4, Kcnip3, Cck, Stx1a, Hrh3, Kcnh7, Sst, Lyve1,
Ptgs2, Chrna5, Gabre, Adra1b, Kcng3, Atp2b4, Agt, Htr2a
small molecular biochemistry Kcnh1, Rxfp2, Cacnb4, Sstr1, Rgs4, Kcnip3, Cck, Stx1a, Pde1a, Hrh3, Acaa2, Ephb6, Gpx3, Tph1, Sst,
Ptgs2, Lyve1, Chrna5, Atp2b4, Adra1b, Htr2a, Agt
Organismal injury and abnormalities Cacna1l, Cacna1g, Kcnip3, Htr1f, Ptgs2, Chrna5, Gabre, Adra1b, Mmp9, Gabra3, Agt, Htr2a
Cell signaling Cacna1g, Rxfp2, Cacnb4, Rgs4, Sstr1, Kcnip3, Cck, Ped1a, Hrh3, Gnat2, Sst, Htr1f, Ptgs2, Adra1b,
Atp2b4, Htr2a, Agt
Drug metabolism Sst, Rgs4, Lyve1, Cck, Ptgs2, Chrna5, Stx1a, Hrh3, Adra1b, Agt, Htr2a
Cell morphology Efna5, Sst, Rgs4, Ptgs2, Adra1b, Mmp9, Agt
Cellular movement Satb2, Sst, Rgs4, Tbr1, Ptgs2, Mmp9, Agt
DNA replication, recombination, and
repair
Sst, Ptgs2, Ped1a, Agt
Nucleic acid metabolism Ephb6, Rxfp2, Cacnb4, Sstr1, Sst, Cck, Ptgs2, Ped1a, Hrh3, Acaa2, Atp2b4, Agt
Canonical pathway
G-protein couple receptor signaling Rxfp2, Rgs4, Sstr1, Htr1f, Tacr3, Pde1a, Hrh3, Adra1b, Htr2a
Cholecystokinin/gastrin-mediated
signaling
Sst, Mef2c, Cck, Ptgs2
Serotonin receptor signaling Tph1, Htr2a
LXR/RXR activation Ptgs2, Mmp9, Agt
Gα12/13 signaling Cdh7, Cdh12, Mef2c
Cytotoxic T lymphocyte-mediated
apoptosis of target cells
Hla-Dq1a, RT1-M6-1/Rt1-M6-2
GABA receptor signaling Gabre, Gabra3
c-AMP-mediated signaling Rgs4, Htr1f, Pde1a, Hrh3
OX40 signaling pathway Hla-Dq1a, RT1-M6-1/Rt1-MG-2
AMPK signaling Pfkp, Chrna5, Adra1b
p< 0.05) compared to non-injured sham animals, whereas only
886 genes in the nicotinamide treated animals showed elevated
expression. Likewise, mRNA levels of 351 genes were decreased
more than 1.5-fold (p< 0.05) compared to non-injured sham
animals, whereas only 247 genes exhibited decreased expression
in the nicotinamide treated animals. Overall, the Venn diagrams
demonstrate the effect of nicotinamide on counteracting the effect
of TBI which results in significantly decreased number of genes
differentially expressed by TBI.
The nicotinamide (CCI animals that received nicotinamide) to
vehicle (CCI animals that received vehicle) comparison evaluates
the effect of nicotinamide treatment by separating out the effect
of the TBI on gene expression. At 24 h post-TBI, the majority
(82%) of the 150 differentially expressed genes in the nicoti-
namide treated animals compared to vehicle were down-regulated
(Table 1). At 72 h post-TBI, there were 119 differentially expressed
genes in the nicotinamide treated animals compared to vehicle
with the majority (90%) being up-regulated. At 7 days post-TBI
(4 days post-nicotinamide treatment), there were only five differ-
entially expressed genes in the nicotinamide compared to vehicle
treated animals.
Ingenuity Pathway Analysis was used to facilitate the identi-
fication of biological themes in the microarray data. IPA shifts
the emphasis from the evaluation of single genes to an evalua-
tion of molecular pathways, networks, and biological functions.
Functional categories were identified by molecular and cellular
functions. Canonical pathways include signaling and metabolic
pathways. IPA was used to generate Figures 3–5; Figures 3 and 4
show bar-graphs for the top 10 functional categories and canonical
pathways for the NAM/Vehicle comparison ranked according to
Frontiers in Neuroscience | Neuropharmacology February 2013 | Volume 7 | Article 21 | 8
Anderson et al. Nicotinamide gene expression in TBI
Table 4 |The effect of NAM treatment (NAM/vehicle) andTBI (vehicle/sham) on differentially expressed genes associated with significant
functional categories and canonical pathways identified by IPA at 24 h post-TBI.
Affymetrix ID Gene symbol Genes 24 h post-TBI 72 h post-TBI
NAM/vehicle Vehicle/sham NAM/vehicle Vehicle/sham
10726550 Adam8 ADAM metallopeptidase domain 8 0.59 2.11 n.s. 2.76
10759999 Alox5ap Arachidonate 5-lipoxygenase activating protein 0.64 3.28 n.s. 3.85
10722992 Anpep Alanyl (membrane) aminopeptidase 0.43 6.51 n.s. 10.18
10702214 Arg1 Arginase 0.66 1.78 n.s. n.s.
10780919 Arl11 ADP-ribosylation factor-like 11 0.58 3.74 n.s. 6.69
10797660 Aspn Asporin 1.52 n.s. n.s. n.s.
10912112 Bcl2a1 BCL2-related protein A1 0.63 2.65 n.s. 5.48
10759834 Brca2 Breast cancer 2 0.61 1.66 n.s. n.s.
10745677 Ccl13l/Ccl3l3 Chemokine (C–C motif) ligand 3-like 1 0.49 6.41 n.s. 3.39
10745670 Ccl6 Chemokine (C–C motif) ligand 6 0.42 6.19 n.s. 3.73
10736702 Ccl7 Chemokine (C–C motif) ligand 7 0.67 4.39 n.s. 3.35
10921163 Ccr1 Chemokine (C–C motif) receptor 1 0.53 4.11 n.s. 2.42
10853240 Cd36 CD36 molecule (thrombospondin receptor) 0.57 5.26 n.s. 7.57
10825809 Cd53 Cd53 molecule 0.61 3.99 n.s. 8.89
10865381 Clec4e C-type lectin domain family 4, member e 0.39 10.51 n.s. 2.66
10862131 Clec5a C-type lectin domain family 5, member A 0.66 4.11 n.s. 3.15
10871957 Csf3r Colony stimulating factor 3 receptor 0.55 4.17 n.s. 3.72
10775896 Cxcl3 Chemokine (C-X-C motif) ligand 3 0.41 5.11 n.s. n.s.
10924245 Cxcr2 Chemokine (C-X-C motif) receptor 2 0.51 5.77 n.s. 1.65
10787197 Cyp4f18 Cytochrome P450, family 4, subfamily 5,
polypeptide 18
1.54 0.54 n.s. n.s.
10827231 Cyr61 Cysteine-rich, angiogenic inducer, 61 0.66 3.95 n.s. 1.50
10794734 F13a1 Coagulation factor XIII, A1 polypepetide 0.54 2.81 n.s. 3.41
10718934 Fcar IgA Fc receptor 0.49 3.51 n.s. n.s.
10769825 Fcer1g Fc fragment of IgE, high affinity I, receptor for;
gamma polypeptide
0.62 3.39 n.s. 6.00
10825153 Fcgr1a Fc fragment of IgG, high affinity Ia, receptor 0.59 3.78 n.s. 4.23
10769788 Fcgr2a Fc fragment of IgG, low affinity IIa, receptor 0.53 3.44 n.s. 4.44
10727321 Gal Galaninprepropeptide 0.63 4.25 n.s. 2.59
10902313 Glipr1 GLI pathogenesis-related 1 0.65 4.33 n.s. 5.43
10926967 Gsta2 Glutathione S-transferase alpha 2 1.63 0.42 n.s. n.s.
10724311 Hbb Hemoglobin, beta 0.62 2.91 n.s. 1.71
10758351 Hcar2 Hydroxycarboxylic acid receptor 2 0.56 2.39 n.s. n.s.
10806946 Hhip Hedgehog-interaction protein 1.56 0.46 n.s. n.s.
10806122 Hmox1* Heme oxygenase (decycling) 1 0.56 8.47 n.s. 11.60
10761128 Hspb1* Heat shock protein 0.54 3.19 n.s. 1.51
10725397 Igsf6 Immunoglobulin superfamily, member 6 0.60 4.52 n.s. 3.87
10849841 Il1b* Interleukin 1 beta 0.62 3.10 n.s. n.s.
10922816 Il1r2 Interleukin 1 receptor, type II 0.49 3.81 n.s. n.s.
10834109 Il1rn* Interleukin 1 receptor antagonist 0.58 5.58 n.s. 4.88
10711299 ltgax Integrin, alpha X 0.64 2.46 n.s. 2.19
10832306 Itgb2 Integrin, beta 2 0.63 3.27 n.s. 5.99
10890024 Nfkbia Nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha
0.63 2.08 n.s. 1.68
10736312 Niacr1 Niacin receptor 1 0.56 2.39 n.s. n.s.
10736312 Nos2 Nitric oxide synthase 2, inducible 0.56 2.91 n.s. n.s.
10761025 Pilra Paired immunoglobulin-like type 2 receptor alpha 0.64 3.07 n.s. 2.90
10877907 Plin2 Perilipin 2 0.50 6.08 n.s. 6.17
10768138 Ptprc Protein tyrosine phosphatase, receptor type, C 0.66 4.62 n.s. 9.39
(Continued)
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Table 4 | Continued
Affymetrix ID Gene symbol Genes 24 h post-TBI 72 h post-TBI
NAM/vehicle Vehicle/sham NAM/vehicle Vehicle/sham
10824695 S100a9* S100 calcium binding protein A9 0.52 3.73 n.s. 1.55
10883530 Sdc1 Syndecan 1 0.66 2.94 n.s. 2.25
10765186 Sell Selectin L 0.51 4.70 n.s. 2.11
10826846 Sgms2 Sphingomyelin synthase 2 0.61 2.27 n.s. 2.46
10921120 Slc6a20 Solute carrier family 6 (proline IMINO transporter),
member 20
1.70 1.99 n.s 2.72
10924286 Slc11a1 Solute carrier family 11 (proton-coupled divalent
metal ion transporters), member 1
0.60 3.76 n.s. 6.02
10851581 Slpi Secretory leukocyte peptidase inhibitor 0.42 4.29 n.s. 3.41
10771919 Sult1d1 Sulfotransferase family 1D, member 1 1.53 0.48 n.s. 0.65
10719187 Sult2a1 Sulfotransferase family 2A,
dehydroepiandrosterone (DHEA)-preferring,
member 1
0.66 n.s. n.s. n.s.
10934608 Tlr13 Toll-like receptor 13 0.61 3.02 n.s. 5.84
10881424 Tnfrsf1b* Tumor necrosis factor receptor superfamily,
member 1b
0.64 2.22 n.s. 2.84
10926277 Trem1 Triggering receptor expressed on myeloid cells 1 0.58 3.35 n.s. 5.43
Results are given as fold change with significance defined as 1.5-fold change, p<0.05. The degree of differential expression of these genes is also shown for the
NAM/Vehicle and Vehicle/Sham contrasts for the 72-h post-TBI time point.
*RT-PCR validated (see Figure 6).
n.s., not significant.
statistical significance (p< 0.05). Figure 5 depicts the second most
significant functional category, i.e., the Cell-to-Cell-Signaling and
Interaction network (p< 0.05) in detail; IPA identified 24 and 27
significant (p< 0.05) functional categories, and 120 and 81 signifi-
cant (p< 0.05) canonical pathways at 24 and 72 h post-TBI for the
NAM/vehicle contrasts, respectively. The differentially expressed
genes associated with each of the top 10 functional categories and
canonical pathways are listed in Tables 2 and 3, whereas their
degree of differential expression for the NAM/Vehicle and Vehi-
cle/Sham contrasts at 24 and 72 h are provided in Tables 4 and 5
respectively.
At 24 h post-TBI, 58 unique genes were over-represented in
the IPA identified significant functional categories and canonical
pathways in the NAM/vehicle contrast with many genes included
in multiple categories (Table 4). The majority of the regulated
genes was involved in cell movement, cell signaling, cell death, and
the inflammatory/immune system and included several cytokines,
cytokine receptors, and chemokines as well as other molecules
involved in the inflammatory/immune response. The expression
of the majority of the regulated genes down-regulated by nicoti-
namide, were up-regulated by TBI as shown in Table 4. At 72 h,
there was still significantly increased expression in the vehicle
treated injured compared to non-injured sham animals in the
majority of the genes affected by nicotinamide at 24 h (Table 4).
However, there was not a continued effect of nicotinamide treat-
ment on the expression of the genes at 72 h although nicotinamide
concentrations were maintained until time of sacrifice.
By 72 h post-TBI, 57 unique genes were significantly over-
represented in the IPA identified significant pathways and
categories in the NAM/vehicle contrast (Table 5). IPA analy-
sis identified a significant effect of nicotinamide on cell-to-cell-
signaling and interactions, molecular transport, small molecular
biochemistry, cell, and drug metabolism. All of the top 10 canoni-
cal pathways identified were signaling pathways. In contrast to the
effects at 24 h, the majority of the genes differentially expressed
were up-regulated by nicotinamide in the NAM/vehicle contrast,
were down-regulated by TBI. The genes differentially expressed
with nicotinamide at 72 h were not affected by nicotinamide
treatment at the earlier 24 h time point (Table 5).
VALIDATION OF MICROARRAY DATA
Validation of microarray data
To validate gene expression changes, 15 genes were selected from
specific pathways of interest. Figure 6 shows the gene expres-
sion results generated via microarray and qPCR (normalized
to β-actin) for the nicotinamide versus vehicle group contrasts;
Figures 6A,B show the data for the 24 and 72-h time points
respectively. The qPCR findings were highly correlated with the
microarray data (Slope= 1.187, Pearson’s R= 0.54).
DISCUSSION
In a study comparing a nicotinamide infusion to two doses of
progesterone on functional recovery in the CCI model, the neu-
roprotective effect of nicotinamide, was equally effective asa low
dose progesterone (10 mg/kg i.p. every 12 h for 72 h; Peterson et al.,
2012). The functional recovery study used the same experimental
conditions (rat strain, injury model, nicotinamide dosing regimen,
and nicotinamide dose) as this study used. In fact, the samples
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Table 5 |The effect of NAM treatment (NAM/vehicle) andTBI (vehicle/sham) on differentially expressed genes associated with significant
functional categories and canonical pathways identified by IPA at 24 h post-TBI.
Affymetrix ID Gene symbol Genes 24 h post-TBI 72 h post-TBI
NAM/vehicle Vehicle/sham NAM/vehicle Vehicle/sham
10802691 Acaa2 Acetyl-Coenzyme A acyltransferase 2 n.s. n.s. 0.66 2.29
10742213 Adra1b Adrenergic, alpha-1B-, receptor n.s. n.s. 1.53 0.49
10811900 Agt Angiotensinogen (serpin peptidase inhibitor, clade
A, member 8)
n.s. 0.55 0.66 n.s.
10767723 Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 n.s. n.s. 1.61 0.53
10746327 Cacna1g Calcium channel, voltage-dependent, T type, alpha
1G subunit
n.s. n.s. 1.56 0.57
10845306 Cacnb4 Calcium channel, voltage-dependent, beta 4
subunit
n.s n.s. 1.55 0.43
10921030 Cck Cholecystokinin n.s. n.s. 2.27 0.38
10763401 Cdh7 Cadherin 7, type 2 n.s. n.s. 1.55 0.38
10813858 Cdh12 Cadherin 12 n.s. 0.64 1.89 0.26
10910133 Chrna5 Cholinergic receptor, nicotinic, alpha 5 n.s. n.s. 3.22 n.s.
10926642 Clic5 Chloride intracellular channel 5 n.s. n.s. 1.52 n.s.
10736697 Ccl2* Chemokine (C-C motif) ligand 2 n.s. 44.15 n.s. 36.50
10930204 Efna5 Ephrin A5 n.s. n.s. 2.28 0.27
10781337 Egr3 Early growth response 3 n.s. n.s. 1.61 0.51
10854961 Ephb6 Eph receptor B6 3.09 n.s. 1.63 0.50
10909987 Exph5 Exophilin 5 n.s. n.s. 1.60 0.31
10940090 Gabra3 Gamma-aminobutyric acid (GABA) A receptor,
alpha 3
n.s. n.s. 1.56 0.46
10935811 Gabre Gamma-aminobutyric acid (GABA) A receptor,
epsilon
n.s. 1.52 1.50 n.s.
10818306 Gnat2 Guanine nucleotide binding protein, alpha
transducing 2
n.s. n.s. 0.61 1.81
10733680 Gpx3 Glutathione peroxidase n.s. n.s. 0.67 2.21
10871939 Grik3 Glutamate receptor, ionotropic, kainite 3 n.s. n.s. 1.67 0.47
10828351 HLA-DQA1 Major histocompatibility complex, class II, DQ
alpha 1
n.s 1.65 0.62 3.58
10852258 Hrh3 Histamine receptor H3 n.s. n.s. 1.58 0.54
10752663 Htr1f 5-Hydroxytryptamine (serotonin) receptor 1F n.s. 0.66 1.59 0.39
10781467 Htr2a 5-Hydroxytryptamine (serotonin) receptor 2A n.s. n.s. 2.37 0.31
10889326 Kcnf1 Potassium voltage-gated channel, subfamily F,
member 1
n.s. n.s. 1.68 0.33
10888131 Kcng3 Potassium voltage-gated channel, subfamily G,
member 3
n.s. n.s. 1.52 0.57
10845725 Kcnh7 Potassium voltage-gated channel, subfamily H
(eag-related), member 7
n.s. 0.65 1.51 0.34
10849655 Kcnip3 Kv channel interacting protein 3, calsenilin n.s. n.s. 2.94 n.s.
10724895 Lyve1 Lymphatic vessel endothelial hyaluronan receptor 1 n.s. n.s. 0.58 3.37
10820223 Mef2c Myocyte enhancer factor 2C n.s. n.s. 1.78 0.38
10907913 Mmp8* Matrix metallopeptidase 8 n.s. 3.24 n.s. 4.15
10842239 Mmp9* Matrix metallopeptidase 9 n.s. 3.36 1.60 n.s.
10795077 Nrsn1* Neurensin 1 n.s. n.s. 2.99 0.39
10782986 Otx2 Orthodenticle homeobox 2 n.s. n.s. 0.41 3.37
10846694 Ped1a Phosphodiesterase 1A, calmodulin-dependent n.s. n.s. 3.68 0.44
10795989 Pfkp Phosphofructokinase, platelet n.s. n.s. 1.70 0.59
10764551 Ptgs2* Prostaglandin-endoperoxide synthase 2 n.s. 1.85 1.72 n.s.
10846694 Pde1a Phosphodiesterase 1A, calmodulin-dependent n.s. n.s. 1.88 0.44
(Continued)
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Table 5 | Continued
Affymetrix ID Gene symbol Genes 24 h post-TBI 72 h post-TBI
NAM/vehicle Vehicle/sham NAM/vehicle Vehicle/sham
10744641 Pitpnm3 PITPNM family member 3 n.s. n.s. 1.57 0.48
10769672 Rgs4 Regulator of G-protein signaling 4 n.s. n.s. 1.82 0.30
10827686 RT1-M6-1 RT1 class I, locus M6, gene 1 n.s. n.s. 2.16 0.50
10827691 RT1-M6-2 RT1 class I, locus M6, gene 2 n.s. n.s. 1.89 0.62
10759923 Rxfp2 Relaxin/insulin-like family peptide receptor 2 n.s. 0.66 1.51 0.65
10836458 Scn2a Sodium channel, voltage-gated, type II, alpha
subunit
n.s. n.s 1.50 0.46
10921274 Satb1 SATB homeobox 1 n.s. n.s. 1.52 0.42
10928191 Satb2 SATB homeobox 2 n.s. n.s. 2.50 0.24
10849943 Slc4a11 Solute carrier family 4, sodium bicarbonate
transporter-like, member 11
n.s. n.s. 1.56 0.65
10751945 Sst Somatostatin n.s. n.s. 1.57 0.49
10884732 Sstr1 Somatostatin receptor 1 n.s. n.s. 1.64 0.43
10930711 St6gal2 ST6 beta-galactosamide α-2,6-siayltransferase 2 n.s. 0.66 1.81 0.45
10802795 St8sia5 ST8 alpha-N -acetyl-neuraminide
α-2,8-sialyltransferase 5
n.s. n.s. 1.61 0.44
10763171 Stx1a Syntaxin 1A (brain) n.s. n.s. 2.16 0.32
10722830 Sv2b Synaptic vesicle glycoprotein 2b n.s. n.s. 1.81 0.43
10819139 Tacr3 Tachykinin receptor 3 n.s. 0.50 1.59 0.29
10845628 Tbr1 T-box, brain, 1 n.s. n.s. 1.90 0.32
10722097 Tph1 Tryptophan hydroxylase 1 n.s. n.s. 0.47 2.23
Results are given as fold change with significance defined as 1.5-fold change, p<0.05. The degree of differential expression of these genes is also shown for the
NAM/Vehicle and Vehicle/Sham contrasts for the 24-h post-TBI time point.
*RT-PCR validated (see Figure 6).
n.s., not significant.
that were used in this study were generated by the same labo-
ratory. Therefore, the phenotypic data described by Peterson and
colleagues can be directly compared to the transcriptional changes
described in this study.
Both the nicotinamide infusion and the low dose progesterone
were significantly more effective than the higher dose progesterone
(20 mg/kg i.p. every 12 h for 72 h; Peterson et al., 2012). Func-
tional recovery was assessed with two spatial memory tasks in the
Morris water maze, the acquisition of a reference memory task
and a reversal learning task. Neuropathological assessments were
conducted in the cortex and hippocampus. Both low dose proges-
terone and nicotinamide improved reference memory acquisition
and reversal learning in the Morris water maze and reduced tissue
loss in the injured cortex and ipsilateral hippocampus compared to
vehicle treatment. As determined in this study, the mechanism of
the effect of nicotinamide on secondary injury pathways involves
effects on inflammatory response, signaling pathways, and cell
death.
INFLAMMATORY RESPONSE
At 24 h, nicotinamide down-regulated the expression of 23 genes
involved in immune or inflammatory processes. All 23 were signifi-
cantly up-regulated in the TBI animals compared to sham controls
and included cytokines, cytokine receptors, and chemokines as
well as others involved in the inflammatory/immune response.
Nicotinamide treatment down-regulated the expression of Il-1β,
Il-receptor type II (Ilr2), Il-1 receptor antagonist (Il1rn), Il-8
receptor β (Il-8rβ) tumor necrosis factor receptor superfamily,
member 1β (Tnfrsf1β), and other genes involved in the inflam-
matory response (Tables 2 and 4). Nicotinamide treatment sig-
nificantly altered the expression of genes involved in Il-10, Trem1,
Il-6, Nf-κB. LXR/RXR, PPAR, NF-κB, and glucocorticoid signaling
pathways at 24 h post-TBI (see Table 2 for specific genes involved in
these pathways). Il-10 is the principal anti-inflammatory cytokine
and inhibits the expression of the pro-inflammatory mediators,
TNFα, Il-6, Il-1, Mmp9, and the generation of Nos2 (Murray and
Smale, 2012). Interesting, neither TBI nor nicotinamide treatment
changed expression of the Il-6 or Il-10 genes themselves at the
time points evaluated. The expression of Trem1 was increased
by TBI and decreased by nicotinamide treatment (Table 4).
Trem1 increases the secretion of pro-inflammatory cytokines and
chemokines (Colonna, 2003). Nicotinamide decreased the expres-
sion of c-type lectin domain family 4, member e (Clec4e), c-type
lectin domain family 4, member d (Clec4d), and S100 calcium
binding protein A9 (S100a9). In the CCI injured animals com-
pared to sham control, TBI increased the expression of Clec4d
and Clec4e, 6- and 10-fold respectively. Clec4d and Clec4e are
induced by inflammatory stimuli and expression leads to cytokine
and chemokine production (Yamasaki et al., 2008; Wong et al.,
2011). S100A9 was increased 15-fold by TBI and regulates vascular
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FIGURE 6 |TaqMan based RT-PCR validation of the microarray data for
the selected genes: Cxc12, chemokine (C-X-C motif) ligand 2; Hmox1,
heme oxygenase 1; Hspa1b, heat shock protein 1b; Il1b, interleukin
1beta; Il1rn, interleukin 1 receptor antagonist; Il8rb, interleukin 8
receptor beta; Mmp8, matrix metallopeptidase 8; Mmp9, matrix
metallopeptidase 9; Niacr1, niacin receptor 1; Nrsn1, neurensin 1;
Ptgs2, prostaglandin-endoperoxide synthase 2; S100a9, S100 calcium
binding protein A9;Tnfrsf1b, tumor necrosis factor receptor
superfamily, member 1b. The RT-PCR data was normalized to the
housekeeping gene β-actin. In order to compare the microarray data to the
RT-PCR data, the microarray data for each gene was divided by the
beta-actin data as it was measured by the microarray analysis. The gray
bars show the microarray data and the black bars display the RT-PCR data
for the contrast. (A,B) Show the data from the 24 and 72-h time point for
the contrasts nicotinamide treated injured animals compared to the
vehicle treated injured animals.
inflammation by promoting leukocyte recruitment (Bourke et al.,
2003; Croce et al., 2009).
Chemokines are regulatory peptides whose major role is to
guide the migration and activation of leukocyte cells into inflam-
matory sites and are considered pro-inflammatory. Chemokines
act with chemokine receptors, G-protein-linked transmembrane
receptors found on surface of target cells. Chemokine ligand 2
(Ccl2) and its receptor chemokine receptor 2 (Ccr2) are both
increased in traumatic and ischemic injuries and have been
implicated in their neuropathologies (Semple et al., 2010c). TBI
significantly increased the gene expression of several chemokines
and chemokine receptors including a 44-fold increase in Ccl2
(Table 5) and 3-fold increased expression in its receptor Ccr2.
In a knock-out mouse model of closed head injury, Ccl2−/−mice
had smaller cortical lesions and decreased neuronal loss (Sem-
ple et al., 2010a,b). Treatment with nicotinamide significantly
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down-regulated the gene expression of Ccl3, Ccl6, Ccl7, Cxc12,
and colony stimulating factor 3 receptor (Csf3r). Nicotinamide
did not decrease the expression of either Ccl2 or Ccr2.
LXR, PPAR, and FXR are nuclear receptors which when acti-
vated, translocate into the nucleus, form a dimer, or heterodimer
with RXR to up or down regulate gene expression. Nicotinamide
decrease the gene expression of only one nuclear receptor, Nfkbia
(Table 4). Nfkbia, is a member of the NF-κ-B inhibitor family,
which are involved in the expression of the pro-inflammatory
cytokines, immune response, and anti-apoptotic genes (Tak and
Firestein, 2001). Polymorphisms of the Nfkbia gene are associ-
ated with susceptibility to autoimmune and inflammatory diseases
(Zhang et al., 2011).
At 72 h, post-TBI, nicotinamide increased the expression of
prostaglandin-endoperoxide synthase 2 (Ptgs2), also known as
COX-2 (Table 5). Ptgs2 can be either pro-inflammatory or anti-
inflammatory (Choi et al., 2009). Ptgs2 is localized in neurons and
is mainly induced in response to inflammatory stimuli. Animal
studies have shown that during the early phase of inflammation,
Ptgs2 is pro-inflammatory, but during the later phases of inflam-
mation dominated by mononuclear cells, Ptgs2 appears to have
anti-inflammatory effects by generating an alternate set of anti-
inflammatory prostaglandins (Gilroy et al., 1999). Nicotinamide
treatment resulted in increased gene expression of the RT1 and
RTII class proteins, the major histocompatibility complex (MHC)
of the rat (Gunther and Walter, 2001). In addition to their function
in adaptive immunity, MHC class 1 molecules have been shown to
be important in brain development, neuronal differentiation, and
synaptic plasticity (Boulanger and Shatz, 2004).
SIGNALING PATHWAYS
At 72 h, nicotinamide increased the expression of several hor-
mones and receptors including the expression of two subunits of
the GABAA receptor, GABAA receptor epsilon and GABAA recep-
tor, α3 (Table 5). The GABAA receptor is a ligand-gated chloride
channel, which binds GABA, the major inhibitory neurotransmit-
ter in the brain. Nicotinamide also increased the gene expression
of the glutamate receptor, ionotropic, kainate 3 (Grik3), serotonin
receptors 1F and 2A, adrenergic α-1B, receptor, histamine receptor
H3, relaxin/insulin-like family peptic receptor 2, and the somato-
statin receptor 1 (Table 5). In the brain, the histamine receptor H3,
is an auto-receptor, inhibiting the release of histamine (Schwartz,
2011). Nicotinamide increased the expression of somatostatin
and its receptor. Somatostatin is a growth hormone-inhibition
hormone, responsible for inhibiting the release of numerous sec-
ondary hormones. Somatostatin has been shown to have anticon-
vulsant activity in models of status epilepticus (Vezzani et al., 1991;
Tallent and Qiu, 2008).
Nicotinamide increased the gene expression of several potas-
sium and sodium voltage-gated ion channels, as well as, cal-
cium voltage-gated ion channels. Specifically, up-regulation of
potassium channels has been associated with diminished neural
excitability. Potassium channel modulators have been proposed
as neuroprotective drugs (Leung, 2010). The expression of synap-
tic vesicle glycoprotein 2b (Sv2b) was decreased with TBI and
increased by nicotinamide. Synaptic vesicle proteins have been
implicated with the etiology of epilepsy (Janz et al., 1999; Feng
et al., 2009). SV2A has been identified as a target of the antiepilep-
tic drug, levetiracetam (De Smedt et al., 2007), and has recently
been found in patients with temporal lobe epilepsy (Janz et al.,
1999; Feng et al., 2009). SV2B has been shown to regulate presy-
naptic Ca2+ signaling and has also been suggested as a target for
treatment of epilepsy (Wan et al., 2010).
APOPTOSIS
The functional category “cell death” was among the top 10 cate-
gories with genes significantly over-represented at the 24-h time
point (Nam/vehicle; Figure 3). Nicotinamide is a low potency
endogenous inhibitor of PARP (Cantoni et al., 1987; Virag and
Szabo, 2002). PARP is an enzyme found in the nuclei of cells and
functions to sense DNA damage, binds to the damaged DNA, cat-
alyzes the cleavage of NAD+ into nicotinamide and ADP-ribose,
and then uses the ADP-ribose to synthesize polymers which attach
to nuclear acceptor proteins (Virag and Szabo, 2002). In addi-
tion, to the effect of PARP on DNA repair and apoptosis, PARP
enhances NF-(B-mediated transcription, and regulates the forma-
tion of inflammatory mediators of inducible nitric oxide synthase
(Nos2). Nitric oxide is a major signaling molecule in the nervous,
immune, and circulatory systems with its action restricted to local
effects due to its instability. Nos2 was up-regulated following TBI
compared to sham controls at 24 h after injury and nicotinamide
decreased the gene expression (Table 4). In the present study there
were no effects of TBI or nicotinamide treatment on the expression
of PARP1, the major isoform present in the nucleus.
CONCLUSION
The proposed mechanism of the beneficial effect of nicotinamide
(anti-inflammatory, anti-oxidant, and preventing apoptosis) has
been based on experimental studies with 10–30 times higher con-
centrations than used in this study (Yang and Adams, 2004; Li et al.,
2006). In this study, we demonstrated that at lower concentrations,
the primary effect of nicotinamide is on inflammatory pathways
at 24 h post-TBI. By 72 h post-TBI, the primary effect of nicoti-
namide is on cell signaling pathways involving neurotransmitters,
neuropeptides, growth factors, and ion channels with little to no
effect on inflammatory pathways.
Another potential promising treatment for TBI is progesterone
which has been studied in preclinical models of TBI for several
decades (Stein and Wright, 2010) and there are currently two large
multi-center clinical TBI studies on-going. In a study evaluating
the effect of the progesterone dose on gene expression in the same
CCI injury model (Anderson et al., 2011), there was a significant
effect of progesterone on inflammatory responses, apoptosis, reg-
ulating the DNA damage response, cell proliferation, and blood
vessel remodeling following TBI. Low dose progesterone treat-
ment significantly altered the expression of 14 and 40 genes at
24 and 72 h, respectively with approximately equal number up-
or down-regulated. At 7 days, low dose progesterone up-regulated
383 of 551 (70%) genes compared to vehicle compared to the lack
of effect of nicotinamide on gene expression at 7 days. In gen-
eral, nicotinamide treatment counteracted the changes in genes
differentially expressed due to TBI, while progesterone treatment
primarily altered expression of genes that were not affected directly
by TBI itself.
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In conclusion, the mechanism of the effect of nicotinamide
on secondary injury pathways involves effects on inflammatory
response, signaling pathways, and cell death. The unique effect
of nicotinamide compared to progesterone on gene expression
suggests that a combination of nicotinamide and low dose prog-
esterone may be an effective combination of treatment for TBI.
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